IL304491A - Methods to reduce cardiovascular risks - Google Patents
Methods to reduce cardiovascular risksInfo
- Publication number
- IL304491A IL304491A IL304491A IL30449123A IL304491A IL 304491 A IL304491 A IL 304491A IL 304491 A IL304491 A IL 304491A IL 30449123 A IL30449123 A IL 30449123A IL 304491 A IL304491 A IL 304491A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- cardiovascular risk
- reducing cardiovascular
- reducing
- risk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954094P | 2014-03-17 | 2014-03-17 | |
| US201462025400P | 2014-07-16 | 2014-07-16 | |
| US201462043182P | 2014-08-28 | 2014-08-28 | |
| EP15305293 | 2015-02-26 | ||
| PCT/US2015/020564 WO2015142668A1 (en) | 2014-03-17 | 2015-03-13 | Methods for reducing cardiovascular risk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304491A true IL304491A (en) | 2023-09-01 |
Family
ID=52648962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304491A IL304491A (en) | 2014-03-17 | 2023-07-16 | Methods to reduce cardiovascular risks |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150284473A1 (https=) |
| EP (2) | EP4403213A3 (https=) |
| JP (3) | JP2017509624A (https=) |
| KR (3) | KR20250006995A (https=) |
| CN (3) | CN106794244A (https=) |
| AU (3) | AU2015231713B2 (https=) |
| CA (1) | CA2942549A1 (https=) |
| EA (1) | EA039310B1 (https=) |
| ES (1) | ES2978990T3 (https=) |
| HU (1) | HUE066839T2 (https=) |
| IL (1) | IL304491A (https=) |
| MX (1) | MX380767B (https=) |
| PL (1) | PL3119810T3 (https=) |
| WO (1) | WO2015142668A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| EP3318255B1 (en) | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| PL3395836T3 (pl) | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2992345T3 (es) | 2011-09-16 | 2024-12-11 | Regeneron Pharma | Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9) |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW202021614A (zh) | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| MX2016006226A (es) | 2013-11-12 | 2016-09-07 | Sanofi Biotechnology | Regimenes de dosificacion para uso con inhibidores de pcsk9. |
| AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| PL3169353T3 (pl) | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
| RU2723018C2 (ru) * | 2014-07-16 | 2020-06-08 | Санофи Байотекнолоджи | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию |
| EP3197492A1 (en) | 2014-09-23 | 2017-08-02 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| JOP20190112A1 (ar) * | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
| US10329620B2 (en) * | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| BR112019020148A2 (pt) | 2017-04-13 | 2020-05-05 | Cadila Healthcare Limited | peptídeo |
| CA3092936A1 (en) * | 2018-03-06 | 2019-09-12 | Sanofi Biotechnology | Use of pcsk9 inhibitor for reducing cardiovascular risk |
| JP7513533B2 (ja) * | 2018-07-02 | 2024-07-09 | アブセントラ，エルエルシー | リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療 |
| CN112912071A (zh) * | 2018-08-17 | 2021-06-04 | 阿玛林制药爱尔兰有限公司 | 降低接受他汀类药物治疗的受试者对外周动脉血运重建的需求的方法 |
| LT3750536T (lt) | 2018-09-24 | 2026-03-25 | Amarin Pharmaceuticals Ireland Limited | Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| JP7692411B2 (ja) * | 2019-11-07 | 2025-06-13 | メディミューン，エルエルシー | 心血管疾患の治療用の内皮リパーゼ抗体 |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| BR112022009587A2 (pt) * | 2019-11-18 | 2022-08-02 | Ad Pharmaceuticals Co Ltd | Anticorpo anti-pcsk9 e uso do mesmo |
| MX2022012752A (es) * | 2020-04-15 | 2023-01-16 | Voyager Therapeutics Inc | Compuestos de union a tau. |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN114848849B (zh) * | 2022-04-25 | 2023-11-17 | 南方科技大学 | Pcsk9蛋白抑制剂在治疗心血管疾病中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| PL3395836T3 (pl) * | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2015
- 2015-03-13 AU AU2015231713A patent/AU2015231713B2/en active Active
- 2015-03-13 CA CA2942549A patent/CA2942549A1/en active Pending
- 2015-03-13 US US14/657,192 patent/US20150284473A1/en not_active Abandoned
- 2015-03-13 EA EA201691847A patent/EA039310B1/ru unknown
- 2015-03-13 KR KR1020247040556A patent/KR20250006995A/ko active Pending
- 2015-03-13 CN CN201580024259.2A patent/CN106794244A/zh active Pending
- 2015-03-13 MX MX2016011975A patent/MX380767B/es unknown
- 2015-03-13 KR KR1020227039740A patent/KR20220157516A/ko not_active Ceased
- 2015-03-13 WO PCT/US2015/020564 patent/WO2015142668A1/en not_active Ceased
- 2015-03-13 EP EP24160083.2A patent/EP4403213A3/en active Pending
- 2015-03-13 HU HUE15712241A patent/HUE066839T2/hu unknown
- 2015-03-13 CN CN202210141133.5A patent/CN114558129A/zh active Pending
- 2015-03-13 KR KR1020167028383A patent/KR20160132459A/ko not_active Ceased
- 2015-03-13 PL PL15712241.7T patent/PL3119810T3/pl unknown
- 2015-03-13 EP EP15712241.7A patent/EP3119810B1/en active Active
- 2015-03-13 JP JP2016556709A patent/JP2017509624A/ja active Pending
- 2015-03-13 CN CN202210141115.7A patent/CN114642661A/zh active Pending
- 2015-03-13 ES ES15712241T patent/ES2978990T3/es active Active
-
2021
- 2021-02-19 AU AU2021201118A patent/AU2021201118A1/en not_active Abandoned
- 2021-10-19 US US17/504,921 patent/US20220144969A1/en not_active Abandoned
-
2022
- 2022-07-22 JP JP2022116854A patent/JP2022141868A/ja active Pending
-
2023
- 2023-07-16 IL IL304491A patent/IL304491A/en unknown
-
2024
- 2024-07-19 JP JP2024115429A patent/JP2024147744A/ja active Pending
- 2024-07-31 AU AU2024205254A patent/AU2024205254A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3119810A1 (en) | 2017-01-25 |
| MX2016011975A (es) | 2016-12-05 |
| CN114642661A (zh) | 2022-06-21 |
| HUE066839T2 (hu) | 2024-09-28 |
| JP2017509624A (ja) | 2017-04-06 |
| US20220144969A1 (en) | 2022-05-12 |
| US20150284473A1 (en) | 2015-10-08 |
| KR20220157516A (ko) | 2022-11-29 |
| AU2024205254A1 (en) | 2024-10-03 |
| EP4403213A2 (en) | 2024-07-24 |
| AU2015231713B2 (en) | 2020-11-19 |
| JP2024147744A (ja) | 2024-10-16 |
| JP2022141868A (ja) | 2022-09-29 |
| KR20160132459A (ko) | 2016-11-18 |
| CA2942549A1 (en) | 2015-09-24 |
| ES2978990T3 (es) | 2024-09-23 |
| EA039310B1 (ru) | 2022-01-12 |
| KR20250006995A (ko) | 2025-01-13 |
| WO2015142668A1 (en) | 2015-09-24 |
| EA201691847A1 (ru) | 2017-01-30 |
| AU2015231713A1 (en) | 2016-10-20 |
| EP4403213A3 (en) | 2024-10-23 |
| AU2021201118A1 (en) | 2021-03-11 |
| CN114558129A (zh) | 2022-05-31 |
| MX380767B (es) | 2025-03-12 |
| EP3119810C0 (en) | 2024-02-28 |
| EP3119810B1 (en) | 2024-02-28 |
| PL3119810T3 (pl) | 2024-07-15 |
| CN106794244A (zh) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304491A (en) | Methods to reduce cardiovascular risks | |
| GB201406151D0 (en) | Method | |
| GB201409558D0 (en) | Method | |
| GB201406155D0 (en) | Method | |
| GB201408119D0 (en) | Method | |
| GB201413240D0 (en) | Method | |
| GB201414496D0 (en) | Method | |
| GB201403470D0 (en) | Method | |
| GB201410022D0 (en) | Method | |
| GB201410101D0 (en) | Method | |
| GB201412802D0 (en) | Method | |
| GB201411500D0 (en) | Method | |
| GB201416849D0 (en) | Method | |
| GB201416675D0 (en) | Method | |
| GB201409234D0 (en) | Method | |
| GB201409128D0 (en) | Method | |
| GB201414181D0 (en) | Method | |
| GB201412736D0 (en) | Method | |
| GB201412226D0 (en) | Method | |
| GB201409101D0 (en) | Method | |
| IL247837A0 (en) | Methods to reduce cardiovascular risks | |
| GB201413929D0 (en) | Method | |
| GB201413612D0 (en) | Method | |
| GB201408649D0 (en) | Method | |
| GB201407971D0 (en) | Method |